Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients (NCT05993390) | Clinical Trial Compass
RecruitingNot Applicable
Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients
South Korea30 participantsStarted 2024-01-11
Plain-language summary
The goal of this clinical trial is to compare the effect of use of reversal agents for neuromuscular blockade in critically ill patients on time for neurological assessment after endotracheal intubation
The main questions it aims to answer are:
* The use of reversal agents for neuromuscular blockade after endotracheal intubation may reduce the time for neurological assessment.
* The types of reversal agents for neuromuscular blockade may affect the time for neurological assessment.
Participants will receive different reversal agents or no medications based on the assigned groups. Thirty minutes after intubation using rocuronium, medication is administered, and the time of initial confirmation of eye opening and movement is recorded.
Researchers will compare 3 groups (sugammadex, neostigmine and control(no medication) to see the difference of time for neurological assessment after endotracheal intubation.
Who can participate
Age range
19 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients 19 years of age or older who were intubated after admission to the intensive care unit.
Exclusion Criteria:
* Patients younger than 19 years of age
* Patients who are not neurologically evaluable or have concomitant neurologic dysfunction
* Patients with neuromuscular disorder
* Patients with a history of drug allergic reactions to sugammadex or neostigmine
* Patients taking or planning to take toremifene, fusidic acid, or hormonal contraceptives
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Time from administration of neuromuscular blocker to the first available neurologic assessment (in minutes)
Timeframe: Time from administration of neuromuscular blocker to first available neurologic assessment (Motor score 6 on GCS, in minutes), assessed up to 48 hours.